New Study Shows Listeria Vaccine for Cervical Cancer Found Safe

NORTH BRUNSWICK, N.J., October 16, 2007 /PRNewswire-FirstCall/
-- Researchers testing a vaccine based on the live bacteria
Listeria, in women with advanced cervical cancer found it to be
safe. The Lovaxin C vaccine being developed by Advaxis Inc. , is
intended to treat cervical cancer and head and neck cancers that
result from the human papilloma virus (HPV). This marked the first
time the vaccine had been treated in humans.

"Our long held belief that live Listeria vaccines are safe, even
in end stage cancer patients, has been confirmed with the results
from our recent Phase I/II study. We have just entered the age of
safe bacterial therapies," said Dr. John Rothman, VP of Clinical
Development.

The immune response that Listeria generates is called "cellular"
immunity, the type needed to attack cancer. Listeria is one of the
strongest stimulators of cellular immunity known. "By redirecting
it against specific tumor types safely, we have created a new, and
potentially very effective, class of cancer therapy," says
Rothman.

Advaxis reported treating fifteen patients in three dosage
groups with thirty-minute 250 ml infusions of Lovaxin C at
three-week intervals. Patients were observed for a total of 111
days. With the exception of two women, all patients had had either
stage IVb advanced, recurrent, or progressive cervical cancer.

Every patient experienced a flu-like syndrome in the
three-to-twelve hours after dosing comprised of fever, chills,
nausea, and occasional vomiting, which is consistent with immune
stimulation. In the lower two doses, symptoms were well tolerated
and resolved with the use of over the counter analgesics and
antihistamines.

Although efficacy was not a primary focus of the trial, efficacy
findings were obtained. Of the seven stable patients, three had
reductions in their tumor mass subsequent to treatment. While most
lesions increased in size, tumor reduction was seen in a number of
lesions and two tumors disappeared completely.

One patient with IVb cancer, who had failed two prior courses of
chemotherapy and a course of radiation was deemed sufficiently
healthy to resume chemotherapy undergo surgery after receiving the
vaccine and was removed from the trial early for this purpose and
currently tumor free.

"This milestone has given us the direction for the continued
development Listeria-based vaccines," said Rothman. Further
vaccines in development target breast, ovarian and lung cancers.
For more information log on to www.advaxis.com.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.